May 03, 2023
Merck has signed a non-binding MoU with the Ministry of Trade, Industry and Energy (MOTIE) and Daejeon City for a new Asia-Pacific BioProcessing Center.
Apr 26, 2023
Over 250 events expected to reach more than 45,000 future scientists on two continents. Hands-on experiments to focus on the impact of contamination on the planet and everyday life.
Apr 24, 2023
Merck, a leading science and technology company, today announced the launch of its Ultimus® Single-Use Process Container Film.
Mar 27, 2023
Partnership to support Beyond Benign’s online learning platform and higher education program
Dec 08, 2022
Merck, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with Synplogen.
Dec 06, 2022
Merck, a leading science and technology company, has acquired Massachusetts-based Erbi Biosystems, a developer of the 2 ml micro-bioreactor platform technology, known as the “Breez™”.
Nov 16, 2022
Merck invests more than € 290 million in its biosafety testing capacity at Rockville, Maryland, USA.
Nov 07, 2022
Merck, a leading science and technology company, today announced a collaboration with Biotheus.
Oct 04, 2022
The Life Science business of Merck has opened a commercial facility for its new Millipore® CTDMO Services offering at the company’s site in Martillac, France.
Sep 21, 2022
Merck, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced the opening of a viral clearance (VC) laboratory as part of the first building phase of its new € 29 million China Biologics Testing Center.
Sep 08, 2022
Merck, a leading science and technology company, strengthens its manufacturing capabilities for single-use assemblies
Aug 08, 2022
Merck, a leading science and technology company, has launched the VirusExpress® 293 Adeno-Associated Virus (AAV) Production Platform, making it one of the first CDMOs and technology-developers to provide a full viral vector manufacturing offering.
Jul 19, 2022
7,000 solar panels produce energy to power 700 homes, Part of We Energies’ “Solar Now” program, bringing more renewable energy to Wisconsin, Reinforces the company’s long-term commitment to renewable energy.
Jul 18, 2022
New facility to manufacture the company’s Hi-Flow™ Plus lateral flow membrane used in rapid diagnostic test kit manufacturing, including Covid-19.
Jun 22, 2022
Merck, announced that its Life Science business sector has doubled its high-potent active pharmaceutical ingredients (HPAPI) production capacity with the expansion of its facility in Verona, Wisconsin.
Jun 14, 2022
Merck collaborates with Agilent Technologies to advance Process Analytical Technologies (PAT).
May 28, 2022
Teaser - ROW
May 23, 2022
The investment, which is the largest in a single site ever for the Life Science business sector, significantly increases membrane manufacturing capacities and enables the construction of a new filtration manufacturing facility.
May 18, 2022
Merck today announced that the Life Science business further enhanced its commitment to Science, Technology, Engineering and Math (STEM) education, with the launch of its 2022 Curiosity Cube® mobile science lab in Europe and North America.
Apr 28, 2022
Merck’s First Asia Pacific Mobius® Single-Use Manufacturing Center in Wuxi, China
Apr 21, 2022
ReadyStream® system offers automated media preparation to conveniently provide a large volume of preheated media, eliminates five time-consuming steps.
Apr 14, 2022
ZooMAb® antibodies first-ever antibody to be recognized for low-environmental impact by My Green Lab
Apr 05, 2022
Merck to become the first company to offer a fully integrated ecosystem for advanced process technologies.
Mar 25, 2022
Teaser Text ROW
Feb 23, 2022
Merck, a leading science and technology company, today announced the closing of the transaction to acquire Exelead, following regulatory clearances and the fulfillment of other customary closing conditions, for approximately USD 780 million in cash. The business combination is expected to enable Merck’s Life Science business sector to provide its customers with comprehensive end-to-end contract development and manufacturing organization (CDMO) services across the mRNA value chain. Merck plans to further invest over € 500 million to scale up Exelead’s technology over the next ten years.
Feb 15, 2022
Merck's Life Science business sector has entered into a collaboration with Waters Corporation to build and expand an Extractables and Leachables (E&L) Reference Library to include ion mobility measurements
Feb 07, 2022
Merck today announced several organizational changes and a new operating model to support the long-term growth strategy of the Life Science business sector and to better serve the evolving needs of its global customers.
Jan 26, 2022
Merck, a leading science and technology company, today announced that the Life Science business sector signed a non-binding Memorandum of Understanding (MoU) with ID Pharma, the advanced medical business within I’rom Group, outlining its planned support of the development and manufacturing of leading-edge gene therapy.
Jan 20, 2022
Merck today announced that Elevian has been selected as the North American winner of its 2021 Advance Biotech Grant Program
Jan 11, 2022
Merck, a leading science and technology company, today announced the expansion of its Stable Isotope Center of Excellence in Miamisburg, Ohio.
Dec 20, 2021
Press Release 1220 Merck Teaser ROW
Dec 06, 2021
Press Release 1206 Merck Teaser -ROW
Nov 23, 2021
Press Release Teaser -ROW
Nov 08, 2021
Press Release 0811 Merck Teaser- ROW
Nov 02, 2021
Press Release 0211 Merck Teaser-ROW
Oct 25, 2021
Press Release 2510 Merck Teaser -ROW
Oct 18, 2021
Press Release 0810 Merck - ROW
Oct 11, 2021
Press Release 1110 Merck Teaser - ROW
Sep 13, 2021
Press Release 0913 Merck ROW Teaser
Jul 24, 2021
Press Release 2407 - ROW
Jul 23, 2021
Press Release Merck 0307 Teaser - ROW
Mar 03, 2020
Merck today launched its LANEXO® Lab Inventory, Safety and Compliance Management System, a new digital laboratory informatics solution designed to drastically reduce time in labs and improve data quality and traceability.
Dec 10, 2018
Merck, a leader in genome editing, today announced a strategic alliance in the CRISPR/Cas9 rodent model market with France-based biotechnology company genOway.
To continue reading please sign in or create an account.Don't Have An Account?